Indoleamine 2,3-dioxygenase (IDO) Activity in Patients With Chronic Lymphocytic Leukemia (CLL) (KLL3)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
MSinisalo, Tampere University Hospital
ClinicalTrials.gov Identifier:
NCT01397916
First received: May 18, 2010
Last updated: March 29, 2012
Last verified: March 2012
  Purpose

The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL) is studied.


Condition
CLL

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: The Activity of Indoleamine 2,3-dioxygenase in Patients With Chronic Lymphocytic Leukemia (CLL)

Resource links provided by NLM:


Further study details as provided by Tampere University Hospital:

Primary Outcome Measures:
  • IDO activity and expression measured by kynurenine/tryptophan ratio in serum and by PCR in peripheral blood mononuclear cells. [ Time Frame: 3 months ] [ Designated as safety issue: No ]
    Indoleamine 2,3 -dioxygenase (IDO) activity in patients with CLL was measured by the serum kynurenine/tryptophan (kyn/trp) ratio and - the expression of INDO (encoding IDO enzyme) and INDOL1 (encoding IDO2 enzyme) genes in peripheral blood mononuclear cells via TaqMan real-time PCR.


Biospecimen Retention:   Samples With DNA

Ido expression


Enrollment: 73
Study Start Date: February 2010
Study Completion Date: December 2010
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
CLL-patients
Controls

Detailed Description:

The Activity of Indoleamine 2,3-dioxygenase in patients with Chronic Lymphocytic Leukemia (CLL)is studied in patients and healthly controls.

  Eligibility

Ages Eligible for Study:   15 Years to 85 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Patients with CLL

Criteria

Inclusion Criteria:

  • Patients with CLL and lymphocyte count > 10 x 109/l

Exclusion Criteria:

  • Acute infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01397916

Locations
Finland
Tampere university Hospital
Tampere, Finland, 33521
Sponsors and Collaborators
Tampere University Hospital
Investigators
Principal Investigator: Marjatta Sinisalo, MD, PhD Tampere University Hospital
  More Information

No publications provided

Responsible Party: MSinisalo, Dr, Tampere University Hospital
ClinicalTrials.gov Identifier: NCT01397916     History of Changes
Other Study ID Numbers: CLL-IDO
Study First Received: May 18, 2010
Last Updated: March 29, 2012
Health Authority: Finland: Finnish Medicines Agency

Keywords provided by Tampere University Hospital:
CLL
IDO

Additional relevant MeSH terms:
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Leukemia
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell

ClinicalTrials.gov processed this record on October 02, 2014